Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Veterans Health
100%
Patient
63%
Diffuse Large B-Cell Lymphoma
49%
Therapeutic Procedure
38%
B-Cell Chronic Lymphocytic Leukemia
32%
Inpatient
32%
Durvalumab
32%
Non Small Cell Lung Cancer
32%
Overall Survival
31%
Progression Free Survival
18%
Diagnosis
17%
Ibrutinib
17%
Life
16%
Veterans Affairs
16%
Combination Therapy
16%
Health Disparity
16%
Veteran
16%
Incidence
16%
Systemic Mycosis
16%
Health
16%
Survival
16%
Chemotherapy
16%
Hepatocellular Carcinoma
16%
Distinct Entity
16%
Thrombocytosis
16%
Chronic Myelogenous Leukemia
16%
Gene Rearrangement
16%
Terminal Illness
13%
Atezolizumab
12%
Bevacizumab
12%
Diseases
11%
Retrospective Study
11%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
9%
Symptomatic Treatment
9%
Toxicity
9%
Chemoradiotherapy
8%
Adult
8%
Prognostic Factor
8%
Analysis
8%
Treatment Response
8%
Isoprenaline
8%
Short Course Therapy
8%
Short Term Survival
8%
Electronic Patient Record
8%
Child-Pugh Score
8%
Chi Square Test
6%
Survival
6%
Brain Metastasis
6%
Brain Edema
6%
Stereotactic Radiosurgery
6%
Nursing and Health Professions
Veteran
49%
Health Care Management
49%
Patient
37%
Chronic Lymphatic Leukemia
32%
Durvalumab
32%
Combination Therapy
25%
Symptom
25%
Survival
19%
Testosterone
18%
Ibrutinib
17%
C Reactive Protein
16%
Health Disparity
16%
Incidence
16%
Systemic Mycosis
16%
Health Equity
16%
Dose
13%
Systematic Review
13%
Terminal Care
13%
Cachexia
9%
Male
9%
Opiate
9%
Advanced Cancer
9%
Inpatient
8%
Chemoradiotherapy
7%
Toxicity
7%
Procedures
7%
Hypogonadism
7%
Hydrocortisone
7%
Occupation (Patient Social Context)
6%
Hospital
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
42%
Non Small Cell Lung Cancer
32%
Durvalumab
32%
Ibrutinib
23%
Adverse Event
19%
C Reactive Protein
16%
Health Disparity
16%
Systemic Mycosis
16%
Incidence
16%
Survival
12%
Atezolizumab
12%
Toxicity
10%
Chemoradiation Therapy
9%
Testosterone
9%
Symptom
9%
Hypogonadism
7%
Cachexia
7%
Tagraxofusp
5%
